Proteome Sciences plc (AIM: PRM)
London flag London · Delayed Price · Currency is GBP · Price in GBX
3.560
+0.050 (1.42%)
Sep 10, 2024, 12:05 PM GMT+1

Proteome Sciences Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally.

The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.

It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates.

The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes.

The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Proteome Sciences plc
Country United Kingdom
Founded 1993
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 35
CEO Mariola Sohngen

Contact Details

Address:
Coveham House
Cobham, KT11 3EP
United Kingdom
Phone 44 20 7043 2116
Website proteomics.com

Stock Details

Ticker Symbol PRM
Exchange London Stock Exchange AIM
Fiscal Year January - December
Reporting Currency GBP
ISIN Number GB0003104196
SIC Code 8731

Key Executives

Name Position
Mariola Sohngen Chief Executive Officer
Abdelghani Omari Chief Financial Officer